Sunil Healthcare
70.10
+1.30(+1.89%)
Market Cap₹71.89 Cr
PE Ratio19.65
IndustryHealthcare
Company Performance:
1D+1.89%
1M-7.68%
6M+2.64%
1Y+2.64%
5Y+2.64%
View Company Insightsright
More news about Sunil Healthcare
19May 26
Sunil Healthcare Schedules Board Meeting on May 29, 2026 to Approve Q4 and FY 2025-26 Audited Financial Results
Sunil Healthcare Limited has informed stock exchanges of a Board of Directors meeting to be held on May 29, 2026, via video conferencing, to consider and approve audited standalone and consolidated financial results for Q4 and the full financial year 2025-26 ended March 31, 2026. The meeting is being convened in compliance with Regulation 29 read with Regulation 33 of the SEBI (LODR) Regulations, 2015. The company has also confirmed that the Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015, remains closed from April 01, 2026 to May 31, 2026, both days inclusive, as previously intimated on March 27, 2026.
 no imag found
16Apr 26
Sunil Healthcare Limited Submits SEBI Compliance Certificate for FY 2025-26
Sunil Healthcare Limited filed its SEBI LODR Regulation 40(10) compliance certificate for FY 2025-26 on April 16, 2026. The certificate, verified by ATCS & Associates Practicing Company Secretaries, confirms timely share transfer processes within 15 days of lodgment through RTA Alankit Assignments Limited. Company Secretary Satyendu Patnaik submitted the documentation to BSE and Calcutta Stock Exchange, demonstrating regulatory compliance for the period April 1, 2025 to March 31, 2026.
 no imag found
07Apr 26
Sunil Healthcare Limited Receives SEBI Compliance Certificate for Q4 FY26
Sunil Healthcare Limited received its quarterly SEBI compliance certificate under Regulation 74(5) for Q4 FY26 ending March 31, 2026. The certificate was issued by RTA Alankit Assignments Limited on April 4, 2026, confirming proper dematerialization procedures for equity shares. Company Secretary Satyendu Pattnaik submitted the certificate to BSE and Calcutta Stock Exchange on April 7, 2026, maintaining regulatory compliance.
 no imag found
06Feb 26
Sunil Healthcare Limited Announces Q3 FY26 Financial Results
Sunil Healthcare Limited announced its Q3 FY26 financial results showing standalone revenue of ₹2,183.73 lakhs and net profit of ₹44.30 lakhs for the quarter ended December 31, 2025. The consolidated results included foreign subsidiaries with revenue of ₹2,233.49 lakhs and net profit of ₹58.52 lakhs. For nine months, standalone revenue reached ₹6,799.69 lakhs with net profit of ₹151.82 lakhs.
 no imag found
05Nov 25
Sunil Healthcare Reports Mixed Q2 FY2026 Results with Standalone Profit and Consolidated Loss
Sunil Healthcare Limited announced its Q2 FY2026 results, showing a standalone profit but consolidated loss. Standalone revenue increased to Rs. 235.76 lakhs in Q2, with a profit of Rs. 7.90 lakhs. Half-yearly standalone revenue reached Rs. 461.96 lakhs with a profit of Rs. 50.75 lakhs. However, consolidated operations reported a Q2 loss of Rs. 5.64 lakhs and a half-year loss of Rs. 18.47 lakhs. The Board approved these results on November 4, 2025, with auditors Singhi & Co. conducting a limited review.
 no imag found
Sunil Healthcare
70.10
+1.30
(+1.89%)
1 Year Returns:+2.64%
Industry Peers
Sun Pharmaceutical
1,800.00
(-0.91%)
Divis Laboratories
9,116.00
(-1.89%)
Torrent Pharmaceuticals
4,752.50
(-0.99%)
Zydus Life Science
1,132.00
(-2.58%)
Cipla
1,340.00
(-0.45%)
Laurus Labs
1,970.70
(-0.47%)
Mankind Pharma
2,499.40
(-0.18%)
Dr Reddys Laboratories
1,209.60
(-1.90%)
Aurobindo Pharma
1,671.10
(-0.05%)
Lupin
2,009.80
(-1.00%)